Literature DB >> 7507036

Drug treatment for hyperactive children. Therapeutic guidelines.

J Elia1.   

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common childhood behavioural disorder and medication is one of the principal treatments. Methylphenidate and dexamphetamine (dextroamphetamine) have a long record of use in children and well proven efficacy, and are the preferred drugs. Current clinical guidelines recommend a trial of methylphenidate and of dexamphetamine for each child meeting criteria for the disorder in order to maximise response rate and minimise adverse effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507036     DOI: 10.2165/00003495-199346050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  53 in total

Review 1.  Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders.

Authors:  J Biederman; J Newcorn; S Sprich
Journal:  Am J Psychiatry       Date:  1991-05       Impact factor: 18.112

2.  Relationship between the delay task and rating scale measures of inattention and hyperactivity.

Authors:  C M Lam; I L Beale
Journal:  J Abnorm Child Psychol       Date:  1989-12

3.  Stimulant drug treatment of hyperactivity: biochemical correlates.

Authors:  J Elia; B G Borcherding; W Z Potter; I N Mefford; J L Rapoport; C S Keysor
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

4.  Metabolism and disposition of methylphenidate-14C: studies in man and animals.

Authors:  B A Faraj; Z H Israili; J M Perel; M L Jenkins; S G Holtzman; S A Cucinell; P G Dayton
Journal:  J Pharmacol Exp Ther       Date:  1974-12       Impact factor: 4.030

5.  State-dependent and main effects of methylphenidate and pemoline on paired-associate learning and spelling in hyperactive children.

Authors:  R S Stephens; W E Pelham; R Skinner
Journal:  J Consult Clin Psychol       Date:  1984-02

6.  Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men.

Authors:  J L Rapoport; M S Buchsbaum; H Weingartner; T P Zahn; C Ludlow; E J Mikkelsen
Journal:  Arch Gen Psychiatry       Date:  1980-08

7.  Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey.

Authors:  D H Langer; K P Sweeney; D E Bartenbach; P M Davis; K B Menander
Journal:  Drug Alcohol Depend       Date:  1986-06       Impact factor: 4.492

8.  Oral pemoline kinetics in hyperactive children.

Authors:  F Sallee; R Stiller; J Perel; T Bates
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

9.  Deprenyl in attention deficit associated with Tourette's syndrome.

Authors:  J Jankovic
Journal:  Arch Neurol       Date:  1993-03

10.  The adolescent outcome of hyperactive girls.

Authors:  S Mannuzza; R Gittelman
Journal:  Psychiatry Res       Date:  1984-09       Impact factor: 3.222

View more
  5 in total

Review 1.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 2.  Safety issues in the use of methylphenidate. An American perspective.

Authors:  M D Rappley
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

Review 3.  Diagnosis and management of children with attention deficit hyperactivity disorder.

Authors:  P Malhi; P Singhi
Journal:  Indian J Pediatr       Date:  2001-06       Impact factor: 1.967

Review 4.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.